Should You Buy That Laser? A CFO's Framework for Med Spa Equipment Decisions

Aesthetic device reps are excellent at selling. The demo is dazzling, the financing is "easy," and the brochure ROI shows the machine paying for itself in months. Some devices genuinely do. Others become $150,000 monuments to optimism, humming in a corner two days a week. The difference is rarely the technology — it's whether anyone ran the numbers before signing.

Start with the only question that matters: utilization

Every device decision reduces to one calculation: how many treatments per month does this machine need to perform to cover its total monthly cost — and is that number realistic for your client base? Total monthly cost means everything: the financing payment, consumables per treatment, the service contract (often $8,000–$15,000 a year and routinely omitted from the rep's math), provider time, and marketing to fill the schedule.

Divide that by your net revenue per treatment (price minus consumables minus provider cost) and you have your break-even treatment count. Then stress-test it: the brochure assumes demand that already exists. Do you have clients asking for this treatment today, or are you hoping the machine creates demand? A device that needs 40 treatments a month to break even, in a practice that can realistically book 15, is not an investment. It's a subscription to regret.

Buy, finance, or lease — the actual trade-offs

Cash purchase is cheapest overall but concentrates risk: $150K of your liquidity in a depreciating asset in a field where technology cycles run three to five years. Very few growing med spas should pay cash for major devices; that capital usually earns more elsewhere in the business.

Financing preserves cash and lets the device's revenue service its own debt — the right default for proven, high-demand technology. Watch two things: personal guarantees (nearly universal — understand what you're signing) and total cost over the term, which reps quote as a monthly payment precisely so you won't multiply it out.

Leasing or fair-market-value arrangements cost more but transfer obsolescence risk — worth real money for trend-sensitive technology that may be outdated before it's paid off. For workhorse categories with long useful lives, ownership usually wins.

Tax treatment (Section 179 and bonus depreciation can front-load substantial deductions in the purchase year) matters and can tilt the timing of a decision — but a deduction only makes a good purchase better. It never makes a bad one good.

The trap of "revenue" thinking

The most common analytical error: counting the device's gross revenue as the win. The real question is incremental contribution — money the device brings in that you wouldn't have earned anyway. If the new machine mostly cannibalizes appointments from services you already offer profitably, its true return is a fraction of its ticket revenue. Model the device against your existing menu, not in isolation.

A simple gate before any signature

Require every equipment decision to clear four hurdles in writing: a break-even utilization number, evidence of existing demand at that level, a total-cost-of-ownership figure for the full term, and a plan for who performs and who markets the treatments. If a purchase can't survive one page of honest math, it won't survive three years of monthly payments.

Before your next device decision, ask us to run the model. It costs a fraction of one payment on a machine you shouldn't have bought.